{"id":767024,"date":"2023-06-29T11:32:34","date_gmt":"2023-06-29T15:32:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/"},"modified":"2023-06-29T11:32:34","modified_gmt":"2023-06-29T15:32:34","slug":"vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/","title":{"rendered":"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN FRANCISCO, June  29, 2023  (GLOBE NEWSWIRE) &#8212; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company\u2019s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir\u2019s corporate social responsibility and environmental, social and governance efforts. She will report to Vir\u2019s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company\u2019s Executive Management Team.<\/p>\n<p align=\"justify\">\u201cSasha has an impressive track record as both a corporate communications and investor relations leader. Her insights and expertise will be invaluable to our executive team as we continue advancing our robust pipeline of innovative therapies aimed at the treatment of infectious diseases,\u201d said Dr. De Backer.<\/p>\n<p align=\"justify\">\u201cI\u2019m honored to join Vir, a company with a strong clinical pipeline and an exciting future ahead targeting significant unmet medical needs around the world,\u201d said Ms. Damouni Ellis. \u201cI look forward to working with Marianne and the exceptional team and Board of Directors at Vir who have established a successful track record of scientific innovation, commitment to patients and a strong employee culture.\u201d<\/p>\n<p align=\"justify\">Ms. Damouni Ellis joins Vir from Marinus Pharmaceuticals, where she served as Senior Vice President, Corporate Affairs and Investor Relations. Previously, she was Director of External Communications and Media Relations for Bayer U.S., where she drove external brand-building strategies in therapeutic areas of oncology, hemophilia, cardio-pulmonary, and women\u2019s health. Earlier in her career, Ms. Damouni Ellis was a Senior Healthcare Journalist at Bloomberg News and Global Editor of BioPharm Insight, formerly a division of the Financial Times Group, which she launched in New York and London.<\/p>\n<p align=\"justify\">She earned her Master of Arts from City, University of London\u2019s Graduate School of Journalism, in the United Kingdom, and her Bachelor of Arts Degree from Richmond, the American International University in London, United Kingdom.<\/p>\n<p align=\"justify\">\n        <strong>About Vir Biotechnology<\/strong><br \/>\n        <br \/>Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201caim,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cpromising\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir\u2019s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir\u2019s strategy and plans; and the potential of, and expectations for, Vir\u2019s clinical pipeline. Many important factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the timing and outcome of Vir\u2019s planned interactions with regulatory authorities; difficulties in obtaining regulatory approval; uncertainty as to whether the anticipated benefits of Vir\u2019s collaborations with other companies can be achieved; difficulties in collaborating with other companies; challenges in accessing manufacturing capacity; clinical site activation rates or clinical trial enrollment rates that are lower than expected; successful development and\/or commercialization of alternative product candidates by Vir\u2019s competitors; changes in expected or existing competition; delays in or disruptions to Vir\u2019s business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir\u2019s filings with the U.S. Securities and Exchange Commission, including the section titled \u201cRisk Factors\u201d contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/N2YxMzA3YzUtNGJjMS00Mjk0LWI1NjgtOTA5Yzc0ZjAxZDI0LTExOTk4OTA=\/tiny\/Vir-Biotechnology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact:\r\nCarly Scaduto\r\nSenior Director, Media Relations\r\ncscaduto@vir.bio\r\n+1-314-368-5189<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) &#8212; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company\u2019s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir\u2019s corporate social responsibility and environmental, social and governance efforts. She will report to Vir\u2019s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company\u2019s Executive Management Team. \u201cSasha has an impressive track record as both a corporate communications and investor relations leader. Her insights and expertise will be invaluable to our executive team as we &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-767024","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) &#8212; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company\u2019s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir\u2019s corporate social responsibility and environmental, social and governance efforts. She will report to Vir\u2019s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company\u2019s Executive Management Team. \u201cSasha has an impressive track record as both a corporate communications and investor relations leader. Her insights and expertise will be invaluable to our executive team as we &hellip; Continue reading &quot;Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-29T15:32:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer\",\"datePublished\":\"2023-06-29T15:32:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/\"},\"wordCount\":802,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/\",\"name\":\"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=\",\"datePublished\":\"2023-06-29T15:32:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/","og_locale":"en_US","og_type":"article","og_title":"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer - Market Newsdesk","og_description":"SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) &#8212; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company\u2019s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir\u2019s corporate social responsibility and environmental, social and governance efforts. She will report to Vir\u2019s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company\u2019s Executive Management Team. \u201cSasha has an impressive track record as both a corporate communications and investor relations leader. Her insights and expertise will be invaluable to our executive team as we &hellip; Continue reading \"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-29T15:32:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer","datePublished":"2023-06-29T15:32:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/"},"wordCount":802,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/","name":"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=","datePublished":"2023-06-29T15:32:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjYyOSM1NjcwNjI0IzIxODgzMzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-appoints-sasha-damouni-ellis-as-executive-vice-president-and-chief-corporate-affairs-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/767024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=767024"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/767024\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=767024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=767024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=767024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}